Key result
The ENERGY trial is a planned proof-of-concept study to determine whether 2 months of trimetazidine improves myocardial energy efficiency in 40 asymptomatic MYH7 mutation carriers.
Why the study?
HCM mutation carriers have decreased myocardial energy efficiency, but whether metabolic drugs can correct this at an early disease stage remains unknown.
Does trimetazidine improve myocardial external efficiency in asymptomatic MYH7 mutation carriers?
Does trimetazidine improve myocardial external efficiency in asymptomatic MYH7 mutation carriers?
The ENERGY trial is a proof-of-concept study designed to determine whether the metabolic drug trimetazidine can improve myocardial energy efficiency in asymptomatic MYH7 mutation carriers, potentially offering a preventive therapy for hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Trimetazidine not indicated for asymptomatic MYH7 carriers; ENERGY trial leaves open preventive metabolic effects in HCM.
Previous studies have shown that hypertrophic cardiomyopathy mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of hypertrophic cardiomyopathy (HCM). The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage. 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomised study design. Directly before and after treatment, study subjects will undergo an [ 11 C]-acetate positron emission tomography/computed tomography (PET/CT) and cardiac magnetic resonance (CMR) scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen the heart consumes to perform work. The ENERGY trial will be the first proof of concept study to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already being used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy.
No takes yet. Share an insight, caveat, or question.
Driel et al. (2019) studied Hypertrophic cardiomyopathy (asymptomatic MYH7 mutation carriers) (n=40). Trimetazidine vs. Placebo was evaluated on Myocardial external efficiency. The ENERGY trial is a planned proof-of-concept study to determine whether 2 months of trimetazidine improves myocardial energy efficiency in 40 asymptomatic MYH7 mutation carriers.
Synapse has enriched 10 related papers. Consider them for comparative context: